This article was downloaded by: [the Bodleian Libraries of the University of Oxford] On: 13 November 2014, At: 05:27 Publisher: Taylor & Francis Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



# Nucleosides and Nucleotides

Publication details, including instructions for authors and subscription information: http://www.tandfonline.com/loi/lncn19

## Synthesis of Racemic 5-Substituted 1-(2,3-Dihydroxypropyl)-6-azauracils and Their Isosteric Isomers

Cherng-Chyi Tzeng $^{\rm a}$ , Long-Chih Hwang $^{\rm a}$ , Chien-Chi Chen $^{\rm b}$  & Dau-Chang Wei $^{\rm c}$ 

<sup>a</sup> School of Chemistry, Kaohsiung Medical College, Kaohsiung City, 807, Taiwan, Republic of China

<sup>b</sup> Culture Collection and Research Center, Food Industry Research and Development Institute, Hsinchu, Taiwan

 $^{\rm c}$  Department of Pharmacy , Tajen Junior College of Pharmacy , Pingtung, Taiwan

Published online: 24 Sep 2006.

To cite this article: Cherng-Chyi Tzeng , Long-Chih Hwang , Chien-Chi Chen & Dau-Chang Wei (1995) Synthesis of Racemic 5-Substituted 1-(2,3-Dihydroxypropyl)-6-azauracils and Their Isosteric Isomers, Nucleosides and Nucleotides, 14:6, 1425-1435, DOI: <u>10.1080/15257779508010702</u>

To link to this article: <u>http://dx.doi.org/10.1080/15257779508010702</u>

## PLEASE SCROLL DOWN FOR ARTICLE

Taylor & Francis makes every effort to ensure the accuracy of all the information (the "Content") contained in the publications on our platform. However, Taylor & Francis, our agents, and our licensors make no representations or warranties whatsoever as to the accuracy, completeness, or suitability for any purpose of the Content. Any opinions and views expressed in this publication are the opinions and views of the authors, and are not the views of or endorsed by Taylor & Francis. The accuracy of the Content should not be relied upon and should be independently verified with primary sources of information. Taylor and Francis shall not be liable for any losses, actions, claims, proceedings, demands, costs, expenses, damages, and other liabilities whatsoever or howsoever caused arising directly or indirectly in connection with, in relation to or arising out of the use of the Content.

This article may be used for research, teaching, and private study purposes. Any substantial or systematic reproduction, redistribution, reselling, loan, sub-licensing, systematic supply, or distribution in any form to anyone is expressly forbidden. Terms

& Conditions of access and use can be found at <u>http://www.tandfonline.com/page/</u> terms-and-conditions

## SYNTHESIS OF RACEMIC 5-SUBSTITUTED 1-(2,3-DIHYDROXYPROPYL)-6-AZAURACILS AND THEIR ISOSTERIC ISOMERS

Cherng-Chyi Tzeng\*, Long-Chih Hwang, Chien-Chi Chen+, and Dau-Chang Wei=

School of Chemistry, Kaohsiung Medical College Kaohsiung City 807, Taiwan, Republic of China

#### Abstract

Acyclic nucleoside analogues of antiviral DHPA and HPMPA have been prepared. Coupling of silylated 6-azauracils with benzyl glycidyl ether and stannic chloride followed by the deprotection with boron trichloride gave 1-(2,3-dihydroxypropyl)-6-azauracils (3) in good overall yields. Reaction of silylated 6-azauracil and epichlorohydrin with or without catalytic stannic chloride afforded 1-(2-chloro-3-hydroxypropyl)-6-azauracil (4a) and 1-(3chloro-2-hydroxypropyl)-6-azauracil (6a) respectively. Coupling of silylated 6azaisocytosine under the same reaction conditions provided 1-(2,3-dihydroxypropyl)-6azaisocytosine (9) and 1-(2-chloro-3-hydroxypropyl)-6-azaisocytosine (10) respectively. None of the compounds exhibited significant antiviral activity against herpes simplex viruses.

#### Introduction

The potent antiviral activity of acyclic nucleosides, 9-(S)-(2,3-dihydroxypropy))adenine (DHPA)<sup>1-4</sup> and 9-(S)-(3-hydroxy-2-phosphonylmethoxypropy))adenine (HPMPA)<sup>5-7</sup> against the virus multiplication prompted the synthetic and biological studies of their analogues. DHPA acts as a potent inhibitor of S-adenosy-L-homocysteine hydrolase

<sup>+</sup>Permanent address: Culture Collection and Research Center, Food Industry Research and Development Institute, Hsinchu, Taiwan

<sup>=</sup>Permanent address: Department of Pharmacy, Tajen Junior College of Pharmacy, Pingtung, Taiwan

(SAH-hydrolase) leading to the accumulation of SAH in the cells which affects the methylation, cellular processes important for viral multiplication. The antiviral spectrum of HPMPA is totally different from that of DHPA and other adenosine analogues. In fact, HPMPA possesses potent and selective activity against a broad spectrum of DNA viruses which are normally insensitive to currently available antiviral drugs.

6-Azauracil, a bioisosteric isomer of uracil, has been found to display a range of biological effects which include antiviral,<sup>8-9</sup> antitumor,<sup>10-11</sup> and antifungal<sup>12</sup>activities. Its ribonucleoside, 6-azauridine, exerts carcinostatic activity against a number of experimental tumors.<sup>13</sup> The mechanism of action has been ascribed to the *in vivo* formation of 6-azauridine-5'-phosphate, a competitive inhibitor of orotidine-5'-phosphate (OMP) decarboxylase with an inhibition constant K<sub>i</sub> of 0.03 mM.<sup>14-15</sup>



In view of the unique biological properties and chemotherapeutic activities exhibited by DHPA, HPMPA, and 6-azauridine, we initiated the present study to explore the new acyclic nucleosides in which the acyclic residue of DHPA is attached to 6-azauracil and 6-azaisocytosine in an attempt to search for more potent antiviral and/or antitumor agents. The 5-position of 6-azauracil was substituted with halogen and alkyl groups whereas the acyclo sugar moiety was modified at 2'- or 3'-position by substitution with a chlorine atom. Other 6-azauracil acyclonucleosides have been previously described.<sup>16-20</sup>

### **Results and Discussion**

The preparation of DHPA analogues (3) is illustrated in Scheme 1. 6-Azauracil  $(1a)^{21-24}$  was silvated with hexamethyldisilazane (HMDS) and then reacted with benzyl glycidyl ether and a catalyst of stannic chloride (SnCl<sub>4</sub>) to furnish 1-(3-benzyloxy-2-hydroxy-propyl)-6-azauracil (2a) in 76% yield. Debenzylation of 2a with either H<sub>2</sub>/palladiun hydroxide or boron trichloride afforded 1-(2,3-dihydroxypropyl)-6-azauracil (3a) in a high yield. When 1-(3-benzyloxy-2-hydroxypropyl)-5-bromo-6-azauracil (2e) was subjected to catalytic hydrogenation, the bromo group was replaced and 3a was produced in 92% yield.



Downloaded by [the Bodleian Libraries of the University of Oxford] at 05:27 13 November 2014

1427

Scheme 1

To obtain 5-bromo-1-(2,3-dihydroxypropyl)-6-azauracil (3e), the starting material 2e should be deprotected by using boron trichloride. Compound 3a can also be prepared directly from the silvlated intermediate of 1a and glycidol in 71% yield. Alkylation of silylated 1a with one molar equivalent of epichlorohydrin and a catalytic amount of SnCl4 in a non-polar solvent (dry toluene or dry dichloromethane) gave an epoxide intermediate which underwent an S<sub>N</sub>1-like ring opening to afford the desired 1-(2-chloro-3hydroxypropyl)-6-azauracil (4a). When the same reaction was run without adding the catalyst (SnCl<sub>4</sub>), 4a was not obtained. The <sup>1</sup>H NMR spectrum of the sole product isolated in this reaction showed two singlets at  $\delta$  0.10 and 7.34 ppm, two doublets at  $\delta$  3.50 and 4.10 ppm, and one multiplet at  $\delta$  4.11 ppm corresponding to OSi(CH<sub>3</sub>)<sub>3</sub>, H-5, CH<sub>2</sub>Cl, NCH<sub>2</sub>, and OCH respectively. The <sup>13</sup>C NMR spectrum supported the <sup>1</sup>H NMR spectrum in confirming the presence of two methylene carbons resonances appeared at  $\delta$  43.73 and 46.91 ppm, one tertiary carbon resonance at  $\delta$  69.34 ppm and the trimethylsilyl carbons resonance at  $\delta$  -0.01 ppm. The mass spectrum which shows the fragments of m/z 241 (M+-HCl) and 228 (M+-CH<sub>2</sub>Cl) indicated the presence of terminal chloromethyl group. The elemental analysis was in accord with the molecular formula C9H16ClN3O3Si, which taken together with spectral evidence suggested a structure of 1-(3-chloro-2trimethylsilyloxypropyl)-6-azauracil (5a). The site of glycosylation of 1 was established as N<sub>1</sub> but not N<sub>3</sub> by the comparison of UV spectra with their reported ribosylated counterparts.<sup>25</sup> Hydrolysis of 5a with aqueous HCl provided 1-(3-chloro-2hydroxypropyl)-6-azauracil (6a) in 83% yield. When the silvlated intermediate of 6azaisocytosine (7) was reacted with benzyl glycidyl ether in the presence of a catalytic SnCl4, 1-(3-benzyloxy-2-hydroxypropyl)-6-azaisocytosine (8) was obtained (Scheme 2). Debenzylation of 8 with BCl<sub>3</sub> afforded 1-(2,3-dihydroxypropyl)-6-azaisocytosine (9). Compound 9 can also be prepared directly from 7 and glycidol. Reaction of the silvlated 7 with epichlorohydrin and SnCl<sub>4</sub> gave the desired 1-(2-chloro-3-hydroxypropyl)-6azaisocytosine (10).

### Antiviral Studies

Antiviral and cytotoxicity assays of the new acyclic nucleosides (**3a-e**, **4a**, **6a**, **9** and **10**) against HSV-1 and HSV-2 in Human Foreskin Fibroblast (HFF) cell were performed by the cytopathic effect (CPE) inhibition assay. None of the compounds were active against HSV-1 and HSV-2 or exhibited toxic effects in uninfected HFF cell when tested up to 100 mM.

#### Experimental

Melting points were determined on a YANACO micromelting point apparatus and are uncorrected. The ultraviolet absorption spectra were obtained on a Beckman UV-Visible



#### Scheme 2

spectrophotometer. Infrared spectra were recorded on a Hitachi 260-30 spectrophotometer. Nuclear magnetic resonance (<sup>1</sup>H and <sup>13</sup>C)spectra were obtained with a Varian Gemini-200 spectrometer. Chemical shifts were expressed in parts per million ( $\delta$ ) with tetramethylsilane as an internal standard. Thin-layer chromatography was run on precoated (0.2 mm) silica gel 60 F-254 plates manufactured by EM Laboratories, Inc., and short-wave ultraviolet light (254 nm) was used to detect the UV absorbing sports. Elemental analyses were carried out on a Heraeus CHN-O-Rapid elemental analyzer.

## 1-(3-Benzyloxy-2-hydroxypropyl)-6-azauracil (2a).

6-Azauracil (1a, 1.13 g, 10 mmol), HMDS (25 ml), and ammonium sulfate (0.1g) were heated under reflux with the exclusion of moisture until a clear solution was obtained. The excess HMDS was removed under vacuo and the residual oil dissolved in dry CH<sub>2</sub>Cl<sub>2</sub> (20 ml). To this solution was added benzyl glycidyl ether (1.64 g, 10 mmol) in dry CH<sub>2</sub>Cl<sub>2</sub> (15 ml) and the resulting reaction mixture was allowed to stir at 0 °C. SnCl<sub>4</sub> (0.76 ml, 6.5 mmol) was added slowly and the reaction was continued for 2 h (monitored by TLC). Methanol (20 ml) was added to quench the reaction and the organic solvent was evaporated to give an residual oil which was purified by silica gel chromatography using a mixed solvent of CHCl<sub>3</sub> : MeOH (8:1) to afford **2a** (2.1 g; 76%). <sup>1</sup>H-NMR (CDCl<sub>3</sub>)  $\delta$ 

3.53 (br s, 1H, OH), 3.57 (m, 2H, NCH<sub>2</sub>), 4.00 (m, 1H, CH), 4.10 (d, 2H, OCH<sub>2</sub>), 4.57 (s, 2H, Ar-CH<sub>2</sub>), 7.34 (s, 5H, Ar), 7.38 (s, 1H, H-5); <sup>13</sup>C-NMR (DMSO- $d_6$ )  $\delta$  53.75 (C-1'), 68.72 (C-2'), 71.38 (C-3'), 73.56 (Ar-C), 135.33 (C-5), 148.70 (C-2), 156.20 (C-4).

The same procedure was used to convert each of the compounds **1b-e** to the respective **2b-e**.

## 1-(3-Benzyloxy-2-hydroxypropyl)-6-azathymine (2b).

Yield 56%; <sup>1</sup>H-NMR (CDCl<sub>3</sub>)  $\delta$  2.20 (s, 3H, CH<sub>3</sub>), 3.69 (m, 2H, NCH<sub>2</sub>), 3.88 (m, 3H, OCH<sub>2</sub> & CH), 4.51 (s, 2H, Ar-CH<sub>2</sub>), 4.92 (br s, 1H, OH), 7.27 (s, 5H, Ar).

## 1-(3-Benzyloxy-2-hydroxypropyl)-5-ethyl-6-azauracil (2c).

Yield 64%; <sup>1</sup>H-NMR (CDCl<sub>3</sub>)  $\delta$  1.13 (t, 3H, CH<sub>3</sub>), 2.56 (q, 2H, CH<sub>2</sub>), 3.56 (m, 2H, NCH<sub>2</sub>), 3.93 (m, 1H, CH), 4.20 (d, 2H, OCH<sub>2</sub>), 4.56 (s, 2H, Ar-CH<sub>2</sub>), 4.92 (br s, 1H, OH), 7.31 (s, 5H, Ar), 10.70 (br s, 1H, NH); <sup>13</sup>C-NMR (CDCl<sub>3</sub>)  $\delta$  10.43 (CH<sub>3</sub>), 23.33 (CH<sub>2</sub>), 53.80 (C-1'), 69.38 (C-2'), 72.33 (C-3'), 74.05 (Ar-C), 149.13 (C-5), 151.09 (C-2), 158.01 (C-4).

## 1-(3-Benzyloxy-2-hydroxypropyl)-5-methylamino-6-azauracil (2d).

Yield 72%; <sup>1</sup>H-NMR (DMSO-*d*<sub>6</sub>)  $\delta$  2.78 (d, 3H, CH<sub>3</sub>), 3.56 (m, 2H, NCH<sub>2</sub>), 4.01 (m, 3H, CH & OCH<sub>2</sub>), 4.56 (s, 2H, Ar-CH<sub>2</sub>), 5.54 (q, 1H, NHCH<sub>3</sub>), 7.32 (s, 5H, Ar), 10.97 (br s, 1H, NH); <sup>13</sup>C-NMR (DMSO-*d*<sub>6</sub>)  $\delta$  28.07 (CH<sub>3</sub>), 53.02 (C-1'), 69.33 (C-2'), 72.24 (C-3'), 73.79 (Ar-C), 144.16 (C-5), 149.44 (C-2), 154.70 (C-4).

## 1-(3-Benzyloxy-2-hydroxypropyl)-5-bromo-6-azauracil (2e).

Yield 80%; <sup>1</sup>H-NMR (CDCl<sub>3</sub>)  $\delta$  3.51 (m, 2H, NCH<sub>2</sub>), 4.04 (m, 3H, CH & OCH<sub>2</sub>), 4.50 (s, 2H, Ar-CH<sub>2</sub>), 7.25 (s, 5H, Ar), 10.41 (br s, 1H, NH); <sup>13</sup>C-NMR (CDCl<sub>3</sub>)  $\delta$  54.40 (C-1'), 69.11 (C-2'), 71.77 (C-3'), 74.03 (Ar-C), 129.68 (C-5), 149.76 (C-2), 153.78 (C-4).

## 1-(2,3-Dihydroxypropyl)-6-azauracil (3a).

Method A: To an ice-salt cooled solution of **2a** (1.39 g, 5 mmol) in dry dichloromethane (30 ml) was added boron trichloride in dichloromethane (5 ml, 1 M solution). The mixture was stirred at the same temperature (-8°C) for 30 min (monitored by TLC to ensure the reaction was completed). A solution (40 ml) of MeOH and CH<sub>2</sub>Cl<sub>2</sub> (1:1) was then added and the resulting mixture was allowed to warm to room temperature. The solvent was evaporated under reduced pressure to give a solid residue which was crystallized from a mixed solvent of CH<sub>2</sub>Cl<sub>2</sub> and MeOH to give **3a** (0.59 g, 85% yield). mp 110 - 111 °C; UV:  $\lambda$ max (log  $\varepsilon$ ) 282 (3.70) (0.1N HCl), 282 (3.75) (H<sub>2</sub>O), 281 (3.59) (0.1N NaOH); <sup>1</sup>H-NMR (DMSO-d<sub>6</sub>)  $\delta$  3.36 (m, 2H, NCH<sub>2</sub>), 3.83 (m, 3H, OCH<sub>2</sub> & OCH), 4.64 (t, 1H, 3'-OH), 4.87 (br s, 1H, 2'-OH), 7.45 (s, 1H, H-5), 12.10 (br s, 1H, NH); <sup>13</sup>C-NMR (DMSO-d<sub>6</sub>)  $\delta$  53.63 (C-1'), 63.63 (C-3'), 68.79 (C-2'), 134.94 (C-5),

148.48 (C-2), 157.15 (C-4); MS: *m*/z 188 (M+1)+; Anal. Calcd for C<sub>6</sub>H<sub>9</sub>N<sub>3</sub>O<sub>4</sub>: C, 38.51; H, 4.85; N, 22.45. Found: C, 38.23; H, 4.94; N, 22.40.

Method B: 6-azauracil (1a, 1.13 g, 10 mmol) was suspended in hexamethyldisilazane (HMDS; 25 ml) and then a catalytic amount of ammonium sulfate (0.1 g) was added. The mixture was heated under reflux with the exclusion of moisture until a clear solution was obtained (ca. 4 h). Excess HMDS was removed under reduced pressure to give silylated intermediate as an oil which was dissolved in dry  $CH_2Cl_2$  (20 ml) and cooled to 0 °C. To this stirred solution was added glycidol (0.74 g, 10 mmol) and SnCl<sub>4</sub> (0.76 ml, 6.5 mmol). The reaction mixture was stirred at 0 °C for 2 h (monitored by TLC). The solvent was evaporated to afford the crude product which was crystallized from a mixed solvent of  $CH_2Cl_2$  and MeOH to give 3a (1.33g, 71% yield).

Method C: Compound 2a or 2e (3 mmol), palladium hydroxide on carbon (600 mg), cyclohexene (5 ml) and absolute ethanol (35 ml) were refluxed for 4 h (monitored by TLC). The resulting solution was filtered and the filtrate evaporated to give the crude product which was crystallized as above to give 3a (88% yield from 2a and 92% yield from 2e).

Method B was adopted for the preparation of 3b-e.

## 1-(2,3-Dihydroxypropyl)-6-azathymine (3b).

Yield 65%; mp 156 - 157 °C (CH<sub>2</sub>Cl<sub>2</sub> and MeOH); UV:  $\lambda$ max (log ε) 283 (3.77) (0.1N HCl), 283 (3.64) (H<sub>2</sub>O), 280 (3.63) (0.1N NaOH); <sup>1</sup>H-NMR (DMSO-*d*<sub>6</sub>) δ 2.06 (s, 3H, CH<sub>3</sub>), 3.34 (m, 2H, NCH<sub>2</sub>), 3.73 (m, 3H, OCH<sub>2</sub> & OCH), 4.48 (t, 1H, 3'-OH), 4.70 (br s, 1H, 2'-OH), 11.94 (br s, 1H, NH); <sup>13</sup>C-NMR (DMSO-*d*<sub>6</sub>) δ 15.97 (CH<sub>3</sub>), 53.72 (C-1'), 63.72 (C-3'), 68.96 (C-2'), 142.78 (C-5), 149.41 (C-2), 157.64 (C-4); MS: *m/z* 201 (M<sup>+</sup>); Anal. Calcd for C<sub>7</sub>H<sub>11</sub>N<sub>3</sub>O<sub>4</sub>: C, 41.79; H, 5.51; N, 20.89. Found: C, 41.59; H, 5.55; N, 20.73.

## 1-(2,3-Dihydroxypropyl)-5-ethyl-6-azauracil (3c).

Yield 60%; mp 148 - 149 °C (CH<sub>2</sub>Cl<sub>2</sub> and MeOH); <sup>1</sup>H-NMR (DMSO-*d*<sub>6</sub>)  $\delta$  1.08 (t, 3H, CH3), 2.47 (q, 2H, CH<sub>2</sub>), 3.35 (m, 2H, NCH<sub>2</sub>), 3.81 (m, 3H, OCH<sub>2</sub> & OCH), 4.64 (t, 1H, 3'-OH), 4.83 (d, 1H, 2'-OH), 11.92 (br s, 1H, NH); <sup>13</sup>C-NMR (DMSO-*d*<sub>6</sub>)  $\delta$  10.49 (CH<sub>3</sub>), 22.78 (CH<sub>2</sub>), 53.52 (C-1'), 64.23 (C-3'), 69.44 (C-2'), 147.17 (C-5), 150.20 (C-2), 158.19 (C-4); MS: *m*/*z* 184 (M<sup>+</sup>-CH<sub>2</sub>OH); Anal. Calcd for C<sub>8</sub>H<sub>13</sub>N<sub>3</sub>O<sub>4</sub>: C, 44.65; H, 6.09; N, 19.53. Found: C, 44.54; H, 6.10; N, 19.42.

### 1-(2,3-Dihydroxypropyl)-5-methylamino-6-azauracil (3d).

Yield 69%; mp 157 - 159 °C (CH<sub>2</sub>Cl<sub>2</sub> and MeOH); UV:  $\lambda$ max (log  $\varepsilon$ ) 311 (3.64) (0.1N HCl), 312 (3.78) (H<sub>2</sub>O), 300 (3.60) (0.1N NaOH); <sup>1</sup>H-NMR (DMSO-*d*<sub>6</sub>)  $\delta$  2.10 (d, 3H, CH<sub>3</sub>), 3.38 (m, 2H, NCH<sub>2</sub>), 3.69 (m, 2H, OCH<sub>2</sub>), 3.88 (m, 1H, CH), 4.62 (t, 1H, 3'-OH), 4.80 (d, 1H, 2'-OH), 6.72 (q, 1H, NHCH<sub>3</sub>), 11.87 (br s, 1H, NH); <sup>13</sup>C-NMR

(DMSO- $d_6$ )  $\delta$  27.57 (CH<sub>3</sub>), 52.18 (C-1'), 63.93 (C-3'), 68.90 (C-2'), 143.65 (C-5), 148.37 (C-2), 154.59 (C-4); MS: m/z 216 (M<sup>+</sup>); Anal. Calcd for C<sub>7</sub>H<sub>12</sub>N<sub>4</sub>O<sub>4</sub>: C, 38.89; H, 5.59; N, 25.92. Found: C, 38.73; H, 5.62; N, 25.73.

## 5-Bromo-1-(2,3-dihydroxypropyl)-6-azauracil (3e).

Yield 82%; mp 138 - 139 °C (CH<sub>2</sub>Cl<sub>2</sub> and MeOH); UV:  $\lambda$ max (log ε) 291 (3.55) (0.1N HCl), 296 (3.62) (H<sub>2</sub>O), 288 (3.67) (0.1N NaOH); <sup>1</sup>H-NMR (DMSO-*d*<sub>6</sub>) δ 3.35 (m, 2H, NCH<sub>2</sub>), 3.77 (m, 3H, OCH<sub>2</sub> & OCH), 5.69 (m, 2H, 3'-OH & 2'-OH); <sup>13</sup>C-NMR (DMSO-*d*<sub>6</sub>) δ 54.08 (C-1'), 63.52 (C-3'), 68.87 (C-2'), 128.10 (C-5), 149.09 (C-2), 154.26(C-4); MS: *m*/*z* 266 (M<sup>+</sup>), 268 (M+2)<sup>+</sup>; Anal. Calcd for C<sub>6</sub>H<sub>8</sub>BrN<sub>3</sub>O<sub>4</sub>: C, 27.09; H, 3.03; N, 15.79. Found: C, 27.10; H, 3.04; N, 15.80.

#### 1-(2-Chloro-3-hydroxypropyl)-6-azauracil (4a).

6-Azauracil (**1a**, 1.13 g, 10 mmol), HMDS (25 ml), and chlorotrimethylsilane (0.1 ml) were heated under reflux with the exclusion of moisture until a clear solution was obtained. Excess HMDS was evaporated to give the residual oil which was dissolved in dry CH<sub>2</sub>Cl<sub>2</sub> (25 ml) and cooled to 0 °C. To this solution was added epichlorohydrin (0.93 g, 10 mmol) in dry CH<sub>2</sub>Cl<sub>2</sub> (15 ml) and the resulting reaction mixture was allowed to stir at 0 °C, SnCl<sub>4</sub> (0.76 ml, 6.5 mmol) was added slowly and the reaction was continued for 2 h (monitored by TLC). Methanol (20 ml) was added to quench the reaction and the organic solvent was evaporated to give an residual solid which was crystallized from ethanol to afford **4a** (1.16 g; 56%). mp 140 - 141 °C; IR (KBr) cm<sup>-1</sup>: 600 (C-Cl), 3200, 3500 (OH); UV: λmax (log ε) 282 (3.31) (0.1N HCl), 280 (3.33) (H<sub>2</sub>O), 278 (3.41) (0.1N NaOH); <sup>1</sup>H-NMR (DMSO-*d*<sub>6</sub>) δ 3.86 (m, 2H, NCH<sub>2</sub>), 3.93 (m, 3H, ClCH & OCH<sub>2</sub>), 5.42 (br, 1H, 3'-OH), 7.46 (s, 1H, H-5), 12.13 (br s, 1H, NH); <sup>13</sup>C-NMR (DMSO-*d*<sub>6</sub>) δ 47.29 (C-1'), 53.31 (C-3'), 67.67 (C-2'), 135.34 (C-5), 148.46 (C-2), 157.14 (C-4); MS: *m/z* 205 (M-1)<sup>+</sup>; Anal. Calcd for C<sub>6</sub>H<sub>8</sub>ClN<sub>3</sub>O<sub>3</sub>: C, 35.05; H, 3.92; N, 20.44. Found: C, 35.06; H, 3.93; N, 20.33.

## 1-(3-Chloro-2-trimethylsilyloxypropyl)-6-azauracil (5a).

6-azauracil (1a, 1.13 g, 10 mmol) was suspended in HMDS (25 ml) and then a catalytic amount of chlorotrimethylsilane (0.1 ml) was added. The mixture was heated under reflux with the exclusion of moisture until a clear solution was obtained (*ca*. 4 h). Excess HMDS was removed under reduced pressure to give silylated intermediate as an oil which was dissolved in dry benzene (25 ml). To this stirred solution was added epichlorohydrin (1.11 g, 12 mmol). The reaction mixture was refluxed for 24 h (monitored by TLC). The solvent was evaporated to give the crude product which was purified by silica gel chromatography using a mixed solvent of CHCl<sub>3</sub> : MeOH (30 :1) to afford **5a** (1.35 g; 49%). mp 109 - 110 °C; IR (KBr) cm<sup>-1</sup>: 600 (C-Cl), 950 (OSi); UV:  $\lambda$ max (log  $\varepsilon$ ) 277 (3.57) (0.1N HCl), 275 (3.52) (H<sub>2</sub>O), 283 (3.63) (0.1N NaOH); <sup>1</sup>H-

NMR (CDCl<sub>3</sub>)  $\delta$  0.10 (s, 9H, OSi(CH<sub>3</sub>)<sub>3</sub>), 3.50 (d, 2H, CH<sub>2</sub>Cl), 4.10 (d, 2H, NCH<sub>2</sub>), 4.11 (m, 1H, OCH), 7.34 (s, 1H, H-5), 10.26 (br s, 1H, NH); <sup>13</sup>C-NMR (DMSO-*d*<sub>6</sub>)  $\delta$ -0.01 (CH3), 43.73 (C-3'), 46.91 (C-1'), 69.34 (C-2'), 135.35 (C-5), 149.77 (C-2), 156.20 (C-4); MS: *m/z* 241 (M<sup>+</sup>-HCl), 228 (M<sup>+</sup>-CH<sub>2</sub>Cl); Anal. Calcd for C<sub>9</sub>H<sub>16</sub>ClN<sub>3</sub>O<sub>3</sub>Si: C, 38.91; H, 5.81; N, 15.13. Found: C, 38.80; H, 5.80; N, 15.28. *1-(3-Chloro-2-hydroxypropyl)-6-azauracil* (6a).

A solution of **5a** (0.28 g, 1 mmol) in 3N HCl (5 ml) was stirred at room temperature for 20 min. The solvent was then evaporated to give a residual solid which was crystallized from H<sub>2</sub>O to give **6a** (0.17 g; 83%). mp 146 - 147 °C; IR (KBr) cm<sup>-1</sup>: 600 (C-Cl), 3250, 3400 (OH); UV:  $\lambda$ max (log  $\varepsilon$ ) 278 (3.39) (0.1N HCl), 278 (3.31) (H<sub>2</sub>O), 283 (3.61) (0.1N NaOH); <sup>1</sup>H-NMR (CDCl<sub>3</sub>)  $\delta$  3.63 (d, 2H, CH<sub>2</sub>Cl), 3.71 (m, 1H, OCH), 3.96 (d, 2H, NCH<sub>2</sub>), 5.42 (d, 1H, OH), 7.48 (s, 1H, H-5), 12.51 (br s, 1H, NH); <sup>13</sup>C-NMR (DMSO-d<sub>6</sub>)  $\delta$  42.77 (C-3'), 47.76 (C-1'), 66.86 (C-2'), 134.74 (C-5), 149.36 (C-2), 156.57 (C-4); MS: *m/z* 169 (M<sup>+</sup>-HCl), 156 (M<sup>+</sup>-CH<sub>2</sub>Cl); Anal. Calcd for C<sub>6</sub>H<sub>8</sub>ClN<sub>3</sub>O<sub>3</sub>: C, 35.05; H, 3.92; N, 20.44. Found: C, 35.09; H, 3.94; N, 20.34.

## 1-(3-benzyloxy-2-hydroxypropyl)-6-azaisocytosine (8).

6-azaisocytosine (7, 1.12 g, 10 mmol) was silvlated and then alkylated as described for the preparation of 2a. The crude product was eluted in a silica gel column with a mixed solvent of CHCl<sub>3</sub> and MeOH (20:1) and the proper fractions were combined and evaporated to give 8 (1.29 g, 47 % yield). mp 154-155 °C; <sup>1</sup>H-NMR (DMSO-*d*6): δ 3.43 (m, 2, NCH<sub>2</sub>), 3.90 (m, 3, OCH & OCH<sub>2</sub>), 4.47 (s, 2, Ar-CH<sub>2</sub>), 5.33 (br s, 1, 2'-OH), 7.09 (s, 2, NH<sub>2</sub>), 7.22 (s, 1, H-5), 7.29 (m, 5, Ar); <sup>13</sup>C-NMR (DMSO-*d*6): δ 55.92 (C-1'), 67.49 (C-2'), 71.94 (C-3'), 72.48 (Ar-C), 139.78 (C-5), 156.35 (C-2), 163.29 (C-4); MS: m/z 277 (M+1)<sup>+</sup>; Anal. Calcd for C<sub>13</sub>H<sub>16</sub>N<sub>4</sub>O<sub>3</sub>: C, 56.51; H, 5.84; N, 20.28. Found: C, 56.44; H, 5.78; N, 20.25.

## 1-(2,3-Dihydroxypropyl)-6-azaisocytosine (9).

Compound **9** was prepared by the same procedure as **3a** in 79% yield (from **8**, method A) and 57% yield (from **7**, method B) respectively. mp 209-210 °C (CH<sub>2</sub>Cl<sub>2</sub> and MeOH); UV:  $\lambda$ max (log  $\varepsilon$ ): 278 (3.51) (0.1N HCl), 278 (3.40) (H<sub>2</sub>O), 276 (3.17) (0.1N NaOH); <sup>1</sup>H-NMR (DMSO-*d*<sub>6</sub>):  $\delta$  3.42 (m, 2, NCH<sub>2</sub>), 3.87 (m, 3, OCH & OCH<sub>2</sub>), 4.85 (t, 1, 3'-OH), 5.25 (d, 1, 2'-OH), 7.18 (s, 2, NH<sub>2</sub>), 7.28 (s, 1, H-5); <sup>13</sup>C-NMR (DMSO-*d*<sub>6</sub>):  $\delta$  55.60 (C-1'), 62.91 (C-3'), 69.16 (C-2'), 139.31 (C-5), 156.01 (C-2), 162.94 (C-4); MS: *m*/*z* 187 (M+1)+; Anal. Calcd for C<sub>6</sub>H<sub>10</sub>N<sub>4</sub>O<sub>3</sub>: C, 38.71 ; H, 5.41; N, 30.09. Found: C, 38.64 ; H, 5.46 ; N, 29.96.

## 1-(2-Chloro-3-hydroxypropyl)-6-azaisocytosine (10).

Compound 10 was prepared from compound 7 by the same procedure as 4a in 31% yield. mp 175-176 °C (EtOH); UV:  $\lambda max$  (log  $\epsilon$ ): 285 (3.71) (0.1N HCl), 287 (3.31)

(H<sub>2</sub>O), 281 (3.26) (0.1N NaOH); <sup>1</sup>H-NMR (DMSO-*d*6):  $\delta$  3.61 (m, 2, NCH<sub>2</sub>), 4.04 (m, 1, ClCH), 3.83 (m, 2, OCH<sub>2</sub>), 5.74 (d, 1, 3'-OH), 7.23 (s, 2, NH2), 7.31 (s, 1, H-5); <sup>13</sup>C-NMR (DMSO-*d*6):  $\delta$  46.62 (C-1'), 55.40 (C-3'), 67.66 (C-2'), 139.38 (C-5), 155.70 (C-2), 162.82 (C-4); MS: *m*/*z* 205 (M<sup>+</sup>); Anal. Calcd for C<sub>6</sub>H<sub>9</sub>ClN<sub>4</sub>O<sub>2</sub>: C, 35.22; H, 4.43; N, 27.38. Found: C, 35.22; H, 4.47; N, 27.38.

## Acknowledgments

We gratefully acknowledge financial support from the National Science Council of the Republic of China (NSC 80-0412-B037-09).

#### References

- 1. H. J. Schaeffer, D. Vogel, and R. Vince, J. Med. Chem., 1965, 8, 502.
- 2. N. Ueda, T. Kawabata, and K. Takemoto, J. Heterocycl. Chem., 1971, 8, 827.
- 3. E. De Clercq and A. Holy, J. Med. Chem., 1979, 22, 510.
- 4. I. Votruba and A. Holy, Collect. Czech. Chem. Commun., 1980, 45, 3039.
- E. De Clercq, A. Holy, I. Rosenberg, T. Sakuma, J. Balzarini, and P. C. Maudgal, Nature (London), 1986, 323, 464.
- 6. A. Holy and I. Rosenberg, Collect. Czech. Chem. Commun., 1987, 52, 2775.
- 7. R. R. Webb II and J. C. Martin, Tetrahedron Lett., 1987, 28, 4963.
- 8. D. Falke and B. Rada, Acta Virol., 1970, 14, 115.
- R. W. Sidwell, G. J. Dixon, S. M. Sellers and F. M. Schabel Jr., *Appl. Microbiol.*, 1968, 16, 370.
- W. A. Creasey, M. E. Fink, R. E. Handschumacker and P. Calabresi, *Cancer Res.*, 1963, 23, 444.
- T. R. Walters, R. J. A. Aur, K. Hernandez, T. Vietti and D. Pinkel, *Cancer*, 1972, 29, 1057.
- 12. G. Matolcsy, Acta Phytopathol., 1966, 1, 245.
- 13. C. A. Pasternak and R. E. Handschumacher, J. Biol. Chem., 1959, 234, 2992.
- 14. H. L. Levine, R. S. Brody and F. H. Westheimer, Biochemistry, 1980, 19, 4993.
- 15. R. S. Brody and F. H. Westheimer, J. Biol. Chem., 1979, 254, 4238.
- 16. B. H. Lazrek and R. P. Panzica, Nucleosides & Nucleotides, 1985, 4, 279.
- 17. S. Purkayastha, B. H. Lazrek, R. P. Panzica, F. N. M. Naguib and M. H. el Kouni, Nucleosides & Nucleotides, 1989, 8, 349.
- C. H. Han, Y. L. Chen and C. C. Tzeng, *Nucleosides & Nucleotides*, 1991, 10, 1390.
- 19. E. C. Wang, H. Y. Chen and C. C. Tzeng, J. Chin. Chem. Soc., 1993, 40, 73.

- 20. Y. L. Chen, S. J. Chen, K. H. Lee, B. R. Huang and C. C. Tzeng, Nucleosides & Nucleotides, 1993, 12, 925.
- 21. J. Gut, Collect Czech Chem. Commun., 1958, 23, 1588.
- 22. M. Bobek, J. Farkas and J. Gut, ibid, 1967, 32, 1295.
- 23. P. K. Chang, J. Org. Chem., 1961, 26, 1118.
- 24. C. C. Tzeng, U. Rychlewska, D. J. Hodgson and R. P. Panzica, J. Heterocycl. Chem., 1986, 23, 33.
- 25. R. H. Hall, J. Am. Chem. Soc., 1958, 80, 1145.